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TNF was originally identified in the serum of mice treated sequentially with Ba-
cillus Calmette-Guerin and endotoxin as a protein, causing hemorrhagic necrosis
of some tumors in animals and producing cytolytic or cytostatic activity in some
tumor cells in culture (1, 2). TNF is a monocyte/macrophage-derived protein ex-
erting a variety of biological actions in addition to the cytotoxicity for tumor cells
(2, 3). Recently, activated monocytes were reported to synthesize a transmembrane
form ofTNF on the cell surface and kill their target tumor cells by either cell-to-cell
contact or local release ofthe TNF secretory component (4) . TNF has been purified
to homogeneity (5) and produced by recombinant DNA technology (6-9). As a re-
sult of these advances, highly purified rTNF has become available for experimental
studies, and TNF has been shown to have multiple biological activities (2, 3). A
variety of normal and transformed tumor cell lines have been shown to have high
affinity cell surface receptors for TNF (10-14) . No correlation was found between
the susceptibility of cells to the cytotoxic activity of TNF and the quantity of TNF
Rs or the binding affinity of TNF to its specific receptor (11, 13). In this study, we
describe an mAb to a human cell surface component (termed anti-Fas mAb) with
associated cell-killing activity that is indistinguishable from the cytolytic activity





Purified human rTNFa and purified human rIFN-1' were kindly
provided by Fujisawa Pharmaceutical Inc., Osaka, and Dr. S. Nagata, Osaka Bioscience In-
stitute, Osaka, respectively. Human rhabdomyosarcoma A673 and colon carcinoma HT29
were kindly provided by Dr. J. Vilhek, New York University. Human foreskin-derived diploid
fibroblast line TM11 was established in this laboratory.
Preparation ofmAb.
￿
BALB/c female mice were immunized with the human diploid fibro-
blast FS-7 cell line and the spleen cells from immunized mice were fused with the NS-1 mouse
myeloma line by standard hybridization technique (15). One hybridoma cell, producing an
mAb with cell-killing activity (termed anti-Fas), was cloned two times by limiting dilution.
Anti-Fas mAb-producing hybridoma cells (2 x 108 cells) were cultured in 500 ml serum-
free ASF104 medium (Ajinomoto Inc., Tokyo) for 5 d at 37°C . The culture fluidwas concen-
trated by ultrafiltration using Omegacell (Filtron, Clinton), and was applied onto a hydroxyl-
apatite column (Asahi Optical Inc., Tokyo). Anti-Fas mAb was eluted by 10-400 mM gradient
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of sodium phosphate, pH 7.4, by using FPLC system (Pharmacia Fine Chemicals, Uppsala).
The eluted anti-Fas mAb was analyzed by SDS-PAGE and the purity was indicated to be >95%.
Assay ofCytolyticActivity.
￿
Cells were cultured in growth medium containing TNF or anti-
Fas as indicated . Cells maintained in suspension culture were stained by trypan blue, and
viable cells were quantified by phase-contrast microscopy. In monolayer cultures, the cyto-
lytic activity was observed under phase-contrast microscopy, and then cell density was quantified
by the staining method using amino black IOB as described by Vilcek et al. (16).
Western Blotting.
￿
Plasma membrane fraction ofU937 cell (300 kg protein/lane), prepared
according to the method of Thom et al. (17), was subjected to 4-20% gradient PAGE in the
presence ofSDS. After electrophoresis, the proteins were transferred to a nitrocellulose sheet
and Fas antigen on the nitrocellulose sheet was detected as follows. The nitrocellulose sheet
was treated with 3% skim milk in PBS for 1 h at 37°C, and then washed by PBS containing
0.1% Tween 20 for 20 min at room temperature. Fas antigen on the nitrocellulose sheet was
reacted with 20 ug/ml of purified anti-Fas IgM or 20 Rg/ml of purified control monoclonal
IgM antibody prepared in this laboratory, which did not bind to human cell surface. The
reaction was visualized by an ABC kit (Vector Laboratories, Inc., Burlingame, CA).
Iodination and Binding Assay ofTNF .
￿
Radioiodination ofTNF using Iodogen (Pierce Chem-
ical Co., Rockford, IL) was performed according to the method of Aggarwal et al. (18). The
receptor binding assay with [ 1251]TNF was performed as described previously in the case of
IFN (19, 20). In brief, cells were incubated with ['251]TNF in RPMI 1640 medium con-
taining 10% FCS at 4°C for 5 h, and cell-bound radioactive TNF was measured.
Flow Cytometric Analysis.
￿
Cell surface Fas antigen and TNRR were quantified as follows.
Cells (5 x 105 cells/sample), washed with PBS, were reacted on ice for 1 h with 0.1 ml PBS
containing I% FCS, 0.02% NaN3, 2 lAg/ml biotinTNF, and 20 pg/ml anti-Fas IgM, and
then for an additional 1 h with 0.1 ml PBS containing 0.02% NaN3, 100 p.g/ml phycoery-
thrin-avidin D (Vector Laboratories, Inc.), and 10 kg/mlaffinity-purified FITC goat anti-mouse
IgM (Cappel Laboratories, Malvern, PA). After washing with PBS at 4°C, cell surface
phycoerythrin-avidin and FITC anti-mouse IgM were quantified at the same time on a flow
cytometer (Epics-CS).
Biotin-conjugated TNF was prepared by incubation of 100 ptg TNF in 0.2 ml PBS with
300 Itg sulfosuccinimidyl 6-(biotinamido) hexanoate (Pierce Chemical Co.) in 30 pl PBS for
20 min on ice, and then unconjugated biotin was removed by chromatography on a PD-10
column (Pharmacia Fine Chemicals).
Results
Comparison oftheCytolyticActivity of TNFandAnti-Fas mAb.
￿
Of >20,000 hybridoma
clones producing mAbs to the human cell surface, one hybridoma produced an mAb
that was cytolytic to various human cells. The mAb was shown to be IgM, and we
termed it anti-Fas antibody. Anti-Fas IgM was purified to homogeneity, and elec-
trophoretically pure anti-Fas IgM killed human cells as well as crude culture fluid
of the hybridoma.
We compared the cell-killing activity of purified anti-Fas IgM and the cytolytic
activity of human rTNF to human rhabdomyosarcoma A673 . The cytolytic activity
of TNF is well known to be enhanced when target cells are treated with IFN-'v,
mitomycin C, actinomycin D, or cycloheximide. Fig. 1 shows that the cell-killing
activity of TNF and anti-Fas is similarly enhanced when target cells are pretreated
with IFN-y or mitomycin C, or post-treated with actinomycin D or cycloheximide.
Moreover, the cell-killing activity of TNF and anti-Fas was enhanced in the same
way when target cells were incubated with the factors at high temperature (39°C).
In IFN-y-treated A673 cells, purified anti-Fas IgM produced 50% and >90% cell
killing at 10 ng/ml and 100 ng/ml (10 pM and 100 pM IgM), respectively. TNF killed





Cytolytic activity ofTNF and anti-Fas IgM for the A673 rhabdomyosarcoma cell
line. A673 cells were cultured with 10 ng/ml purified humanrTNF or 30 ng/ml purified anti-Fas
IgM for 15 h at 37°C, and cytolytic activity was observed under phase-contrast microscopy (A) .
Cells were pretreated for 24 h at 37°C with 200 IU/ml purifiedhumanrIFN-y (B) or 0.08 hg/ml
mitomycin C (D) before the treatment with TNF or anti-Fas IgM . Cells were incubated with
TNFor anti-Fas at 39°C (C). Cellswere cultured at 37°C for 4h with 50 lag/ml cycloheximide
(E) or 2 .5 Wg/ml actinomycin D (F) after the treatment with TNF or anti-Fas at 37°C .
400pM TNF trimer), respectively. Thus, the molar concentrations of anti-Fas and
TNF required to kill A673 cells are almost the same.
The cytolytic activity of TNF and purified anti-Fas IgM were also compared by
time-lapse cinematography under a phase-contrast microscope (Fig. 2) . HumanA673
cells, pretreated with IFN-y, were cultured with TNF or anti-Fas IgM at 38.5°C.
Signs of cytotoxicity became detectable after 2 h of incubation with either TNF or
anti-Fas IgM, with the number of killed cells increasing gradually thereafter. Al-
most all cells were killed by 15 h of incubation with either TNF or anti-Fas IgM.
Target Cell Specificity of TNFand Anti-Fas IgM. We analyzed the sensitivity to the
cell-killing activity of anti-Fas IgM in several human cell lines that varied in their
response to the cytolytic action ofTNF (Table I) . All human cell lines sensitive to
the cytolytic activity of TNF were sensitive to anti-Fas IgM, and the cytolytic ac-
tivity of both factors was similarly enhanced by the treatment with IFN-y . It has
been demonstrated that TNF and IFN-y can exert amarked synergism in the cyto-
toxic activity on humancolon carcinoma cell line HT29, which is almost insensitive
to the cytolytic activity ofTNF in the absence ofIFN-y (21) . Our results show that
HT29 cells are insensitive to the cytolytic activity of either TNF or anti-Fas, and
pretreatment withIFN-yrenders HT29 cell sensitive to the cytolytic activity ofboth1750
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FIGURE 2 .
￿
Comparison ofthe cytolytic activity ofTNF and anti-FasIgM . A673 cells pretreated
with 200 IU/ml IFN-.y were incubated with 30 ng/ml TNF or 100 ng/ml purified anti-Fas IgM
at 38 .5°C, and the cytolytic activity ofTNF and anti-Fas was monitored continuously by time-
lapse cinematography under a phase-contrast microscope . Frames of the cinema after 0, 5, 10,
and 15 h of incubation were photographed .
TABLE I
Target Cell Specificity of the Cytolytic Activity of TNF and Anti-Fas IgM
Cells in growth medium (10 5 cells/ml) were cultured with or without 200 IU/ml IFN-,y for
24 h and then incubated with 20 ng/ml TNF or 50 ng/ml purified anti-Fas IgM for 15 h . The
cytolytic activity wasquantified as described in Materials and Methods . In the maximum response
( + + + + ), 75-100% cells are killed ; + + + denotes a strong response, that is, 50-75% cells
killed ; + + , a moderate response of 25-50% cells killed; +, a minimal response of <25










Histiocytoma U937 + + + + + + + + + + + +
Promyelocytic leukemia HL60 + + + + + + + + +
Rhabdomyosarcoma A673 + + + + + + + + + + + +
Amnion-derived FL - + + + + + +
Colon carcinoma HT-29 - + + + + - + + + +
T lymphoblastoid MOLT4B + + + +
Diploid fibroblast FS-7 - - + + + +
Diploid fibroblast TM-11 - - + + + +
Burkitt lymphoma Daudi - - - -YONEHARA ET AL .
￿
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TNF or anti-Fas IgM . However, human diploid fibroblasts FS-7 and TM-11, which
were insensitive to the cytolytic activity of TNF, were sensitive to the cell-killing
activity of anti-FasIgM . Burkittlymphoma line Daudi was insensitive to both factors .
We couldnot detect a significant number ofTNFRs and Fas antigen on Daudi cells
(data not shown) .
Characterization of FasAntigen by Western Blotting
￿
Fas antigen on U937 cells was
characterized by western blotting . Plasma membrane fraction ofU937 cell was sub-
jected to PAGE in the presence ofSDS . After electrophoresis, the proteins were trans-
ferred to a nitrocellulose sheet and Fas antigen on the nitrocellulose sheet was ana-
lyzed . Fig . 3 shows a specific band with a molecular weight of 200,000 on the
nitrocellulose filter treated with anti-Fas IgM. This band was not observed when
control mouse IgM was used instead of anti-Fas IgM . Anti-Fas-specific band with
molecular weight of 200,000 was also observed when SDS-PAGE was carried out
in the presence of2-ME . The molecular weight of Fas antigen is different from the
molecular weight of the TNFR, reported to be 65,000 t 32,000 (22) .






of Fas antigen on U937 cell . Fas
antigen on U937 cell was ana-
lyzed by western blotting as de-
scribed in Materials and Meth-
ods. Molecular weight standards
are shown on the left .1752
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FIGURE 4.
￿
Radioactive TNFbindingto U937 andTMll cells
pretreated with anti-Fas IgMat 37°C. U937 cells (A)andTMll
cells (B) were cultured in growth medium with or without 10
wg/ml purified anti-Fas IgM at 37°C. After a 5-hincubation,
U937 cells (3.5 x 106 cells/ml) andTMII cells(2.9 x 105 anti-
Fas-treated cells/ml and3.6 x 105 untreated cells/ml) were in-
cubatedwith radioactive TNF(4,500 cpm and0.62 ng/ml) in
the presence (/)or in the absence (0) ofunlabeledTNF (I
wg/ml). Radioactivity bound on cells was measured in dupli-
cate as described in Materials and Methods.
lecular weight of Fas antigen was shown to be different from that of the TNFR,
although anti-Fas is similar to TNF in its cytolytic activity. To determine whether
there is a relationship between the cytolytic activity ofanti-Fas and TNF, we ana-
lyzed whetherTNFRwas downregulated bythe treatmentwith anti-Fas IgM. U937
and TM11 cells were incubated with 10,ug/ml ofpurified anti-Fas IgM at 37°C for
5 h, and then binding ofradioactiveTNFto cells was measured. InU937 cells, which
are sensitive to the cytolytic activity ofTNF, incubation with anti-Fas at 37°C did
result in decreased binding of TNF (Fig. 4 A). On the other hand, incubation of
TNF-insensitive TM11 cells with anti-Fas at37°C didnot result indecreasedbinding
of TNF (Fig. 4 B). Scatchard analysis indicated that incubation of U937 cells with
anti-Fas at 37°C for 5 h decreased the numberofspecificTNFbinding sites to<20%,
whereasincubation ofTMll cells with anti-Fasdidnotdecrease the number ofspecific
TNF binding sites (data not shown).
Co-downregulation of TNF-R and Fas Antigen by the Treatment with Either Anti-Fas or
TNF. To show the co-downregulation of Fas antigen and TNFR, we quantified
simultaneouslycell surfaceFasantigen and TNFbindingon aflowcytometer(Epics-
CS) by using anti-Fas IgM and FITC-conjugated anti-mouse IgM, and biotin-
conjugated TNF and phycoerythrin-conjugated avidin, respectively (Fig. 5). The
binding ofbiotinTNF to U937 cells was completely inhibited by a 100-fold excess
of unlabeled TNF (Fig. 5 AI), indicating that the binding of biotinTNF to U937
cell was specific.
WequantifiedbothFasantigen andTNFbindingmolecule onU937 cellspretreated
with purified anti-Fas IgM (Fig. 5 A). Fas antigen andTNF binding on U937 cells,
pretreated with anti-Fas IgMfor 60 min on ice, were simultaneously downregulated
by the incubation with anti-Fas at 37°C. After a 10-min incubation at 37°C, a por-
tion ofTNFRswasco-downregulated with Fas antigen, and after 60 min incubation
at 37°C, almost all Fas antigen and TNF-Rs were co-downregulated.
We alsoquantified both TNFR and FasantigenonU937 cells, treated with biotin-
conjugated TNF U937 cells, pretreated with biotin-conjugated TNF for 60 min
on ice, were incubated at37°C for 10 min or 1 hin thepresence ofbiotin-conjugated
TNF, and then the amounts ofcell surface Fas antigen and TNF bindingwere mea-
sured (Fig. 5 B). A portion ofFas antigen was co-downregulated with TNF binding
after a 10-min incubation at 37°C. After a 1 h incubation at 37°C with TNF, about






andFas antigen on humanU937 cells treated
with anti-Fas IgM or TNF . U937 cells were
pretreated with 10 Ftg/ml anti-Fas IgM (A) or
2 Irg/ml biotin-conjugated TNF (B) for 1 h
on ice and then for 0 min (A2, B2), 10 min
(A3, B3), or 60 min (A4, 134) at 37°C . There-
after, cells were stained by anti-Fas IgM and
biotin-conjugatedTNF for 1 hon ice, followed
by FITC anti-mouse IgM and phycoerythrin-
avidin, and TNFR and Fas antigen were
quantified simultaneously on a flow cytom-
eter . Cells were pretreated with control puri-
fied monoclonal IgM antibody instead of anti-
Fas IgM and stained with control IgM and
biotinTNFin the presence of 100-fold excess
ofunlabeledTNF(A]) . Cells were pretreated
with unlabeledTNFinstead of biotin-conju-
gatedTNFand stained with controlIgMand
unlabeled TNF (BI) .
We also analyzed whether Fas antigen was co-downregulated with theTNFR on
diploid fibroblasts TM11 and colon carcinoma HT29 cells, both of which were in-
sensitive to the cytolytic activity ofTNF . The quantity of Fas antigen was measured
by means of indirect immunofluorescence on a flow cytometer before and after the
incubation with TNF at 37°C . The amount of Fas antigenon neither cell decreased
by the treatment with TNF (Fig . 6).TNFbindingon either cell, however, was down-
regulatedby the treatment with TNF (datanot shown) . Thus, Fasantigen andTNF
binding molecules on TM11 and HT29 cells are not co-downregulated .
Since HT29 cell can be rendered sensitive to the cytolytic activity ofTNF by the
treatment with IFN-.y (Table I), we measured the amounts of Fas antigen on HT29
cells pretreated with IFN- -y (Fig. 6) . The amount of Fas antigen on HT29 cells was
FIGURE 6 .
￿
Flow cytometry analysis ofFas antigen on TM11 cell (A andB) andHT29 cell (C-F) .
Cells in 3.5-cm plastic dishes were incubated with 2 wg/ml TNF for 1 h on ice (A, C, and E)
and then for 1 h at 37°C (B, D, and F) . Thereafter, cells were detached from the culture dishes
by a rubber policeman. And cells were reacted on ice for 1 h with 0.1 ml PBS containing 20
jag/ml anti-Fas IgM or 20 jig/ml control purified mouse IgM instead of anti-Fas, and then for
an additional 1 h with 0.1 ml PBS containing 10 hg/ml affinity-purified FITC goat anti-mouse
IgM . Afterwashing with PBS at 4°C, cell surface FITC anti-mouse IgM were quantified on
a flow cytometer (Epics-CS) . HT29 cells were preincubated with (E and F) or without (C and
D) 200 IU/ml IFN-y for 15 h at 37°C before the incubation with TNF .1754
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shownto markedly increaseby thetreatmentwithIFN--y. Moreover, IFN-y-treatment
convertedFas antigen on HT29 cell tobe downregulatedby thetreatment with TNF
at 37°C.
Discussion
TNF is cytolytic or cytostatic for some types of tumor cells, and nontransformed
cell lines are generally resistant to the cytolytic and cytostatic actions of TNF (2,
11, 13, 16, 21). There exists, however, indistinguishable TNFR on tumor cells, sen-
sitive to the cytolytic activity ofTNF, and nontransformed cells (11, 13). It is unac-
countable how to determine the sensitivity ofcells to the cytolytic activity ofTNF.
We suggest here that the cytolytic activity ofTNF is mediated by cell surface Fas
antigen with a 200,000 mol wt associated with the TNFR, and that TNFR is not
associated with Fas antigen on cells insensitive to the cytolytic activity of TNF.
In this study, we investigated an mAb anti-Fas IgM for human cell surface with
associated cytolytic activity. The cytolytic activity of anti-Fas is indistinguishable
from the cytolytic activity ofTNF. The cytolytic activity ofeither anti-Fas orTNF
was enhanced when target cells were treated with IFN-y, metabolic inhibitors, and
high temperature (Fig. 1). Moreover, we could not distinguish the cytolytic activity
of anti-Fas from TNF when observed by the time-lapse cinematography under a
phase-contrast microscope (Fig. 2). Anti-Fas IgM is shown to be agonistic mAb to
TNF in the cytolytic activity.
Human cells sensitive to the cytolytic activity of TNF are sensitive to anti-Fas,
but human cells sensitive to anti-Fas are not necessarily sensitive to the cytolytic
activity of TNF (Table I). Human colon carcinoma HT29 is sensitive to the cyto-
lytic activity ofneither TNF nor anti-Fas, and IFN-y treatment renders HT29 cells
to be sensitive to both TNF and anti-Fas. Tsujimoto et al. (14) reported about two-
fold increase of TNFRs on HT29 cell by the treatment with IFN-y. It seems to
be difficult, however, to explain the conversion ofHT29 cell by a twofold increase
of TNFRs. In contrast, the amount of Fas antigen on HT29 cell is shown to in-
crease exceedingly by the treatment with IFN-y (Fig. 6). This marked increase of
Fas antigen could be responsible for the conversion of HT29 cells in sensitivity to
the cytolytic activity of anti-Fas as well as TNF.
Fas antigen was shown to be different from the TNFR since (a) the molecular
weight ofFas antigen (200,000) is different from the molecular weight ofthe TNFR
that was shown to be 65,000 t 35,000 (22); and (b) the abundance ofTNFRs on
different cells does not correlate with the amounts ofFas antigen (data not shown).
Thus, Fas antigen is not identical with the TNFR, although anti-Fas is similar to
TNF in the cytolytic activity.
Fasantigen on cells sensitiveto thecytolytic activity ofTNF seemsto be associated
withtheTNFR, because TNFR andFas antigen on sensitive cellsareco-downregu-
lated bythetreatmentwith either anti-Fas orTNF (Fig. 5). In contrast, Fas antigen
and TNFRoncells insensitive tothe cytolytic activity ofTNFarenotco-downregu-
lated (Fig. 6). Human colon carcinoma HT29 was shown to be rendered sensitive
to both TNF and anti-Fas by treatment with IFN-y (Table 1), and Fas antigen on
IFN-y-treated HT29 cellisshown tobedownregulated bytreatment with TNF(Fig.
6). There exists good correlation between the sensitivity to the cytolytic activity ofTNF and the codownregulation of Fas antigen and TNFR. Thus, TNFR may be
associated with Fas antigen on cells sensitive to the cyolytic activity of TNF but is
not associated with Fas antigen on TNFinsensitive cells.
It is well known that cellular macromolecular synthesis is not necessary to the
cytolytic activity of TNF, although other activities ofTNF may be caused by TNF
induced gene products. The cytolytic activity of TNF must be different from other
activities of THE We analyzed whether other biological activities of TNF were as-
sociated with anti-Fas. Fibroblast growth-stimulating activity and HLA-inducing
activity are not associated with anti-Fas (datanot shown). Fas antigen seems to mediate
only the cytolytic activity of THE Further studies on the purification and cDNA
cloning of Fas antigen are in progress.
Summary
We have prepared an mAb specific for a human cell surface component (termed
anti-Fas mAb). Anti-Fas shows cell-killing activity that is indistinguishable from the
cytolytic activity of THE Fas antigen was characterized by western blotting, indi-
cating that Fas antigen is a cell surface protein with a molecular weight of 200,000,
which is different from the molecular weight of TNFR. Fas antigen, however, is
co-downregulated with the TNFR when cells sensitive to the cytolytic activity of
TNF are incubated with either TNF or anti-Fas. In contrast, Fas antigen on cells
insensitive to TNF is not co-downregulated with the TNFR. We suggest that the
cell-killing activity of TNF is mediated by Fas antigen associated with the TNFR.
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